Article
AstraZeneca's Imfinzi Combo Approved In US For Muscle-Invasive Bladder Cancer Treatment
Neutral
0.0
−100 Bearish
0
+100 Bullish
(RTTNews) - British drug major AstraZeneca Plc.'s (AZN, AZN.L) Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in th
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
NASDAQ Markets
Published
Mar 31, 2025 · 6:27 am
Article ID
93848997835363824228
Original URL
Open source
Sentiment Signal
Neutral
0.0
−100Neutral+100
More Like This